340P - The study of MIB-1 LI and CD-34 as a marker of proliferative activity and angiogenesis in different grades of meningioma

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Central Nervous System Malignancies
Presenter Harishkumar Bohra
Citation Annals of Oncology (2016) 27 (6): 103-113. 10.1093/annonc/mdw367
Authors H.R. Bohra
  • Pathology, All India Institute Of Medical Sciences(AIIMS), 342005 - Jodhpur/IN



Meningiomas comprise 24-30% of all tumours occurring in the central nervous system. Conventional morphologic criteria as studied in routine Hematoxylin and Eosin stained sections ( H and E) may not be accurate in grading and assessing prognosis in small stereotactic biopsy specimens. Thus, the need for objective methods for assessing tumour biology. Prolifereative index using MIB -1 labelling index is helpful in grading and prognosis of tumours. Angiogenesis is a key event in the spread of tumours and denotes a poor prognosis. Intratumoral microvessel density (MVD) helps in quantification of angiogenesis.


Paraffin blocks of 30 surgically resected cases, 10 each of Grade I, II and III meningiomas were reviewed. Tumours were graded and subtyped as per WHO criteria. Immunohistochemical staining was done for proliferative index with Ki-67 and for angiogenesis with CD 34 antibodies. Statistical analysis was performed using Mann – Whitney U test. p value of 


The male to female ratio overall was 1:1.The age of the patients ranged from 18-81 years. 73% of patients had raised intracranial pressure and 18.4% of patients presented with seizures. The mean +/- SD MIB-1 LI was 1.14 +/-0.84, 8.94 + /-2.73 and 35.62 +/-4.44 in grade I, II and III tumours respectively which was statistically significant. (p< 0.01). The mean +/- SD MVD was 49.67 +/- 22.35, 41.37 + /-7.45 and 47.86 +/- 10.77 respectively in grade I, II and III tumours respectively. was statistically non significant ( p > 0.05).


MIB-1 LI is an important complementary tool to accurately grade meningothelial tumours and assess tumour biology. Specific cycling endothelial markers along with CD 34 MVD could be used to assess the prognosis of these tumours.

Clinical trial identification

Not applicable in this study.

Legal entity responsible for the study

National Board of Examinations, New Delhi. Base Hospital, Delhi Cantt, New Delhi.


Base Hospital Delhi Cantt, New Delhi.


All authors have declared no conflicts of interest.